UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 21, 2004 |
Date of Report (Date of earliest event reported) |
NPS PHARMACEUTICALS, INC. |
(Exact name of registrant as specified in its charter) |
Delaware | 0-23272 | 87-0439579 |
(State or other jurisdiction of | (Commission File Number) | (I.R.S. Employer |
incorporation) | Identification Number) |
420 Chipeta Way |
Salt Lake City, Utah 84108 |
(Address of principal executive offices) |
(801) 583-4939 |
(Registrant’s telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
[_] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[_] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[_] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[_] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Events. |
On October 21, 2004, the Company issued a press release regarding TOP study data presented in connection with the American College of Rheumatology scientific meetings in San Antonio, Texas, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
(c) | Exhibits |
99.1 | Press Release issued by the Company on October 21, 2004. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 21, 2004 | NPS PHARMACEUTICALS, INC. |
By: /s/ HUNTER JACKSON | |
Hunter Jackson | |
CEO, President and Chairman of the Board |
EXHIBIT INDEX
Exhibit | |
Number | Description |
99.1 | Press Release issued by NPS Pharmaceuticals, Inc. on October 21, 2004. |